The estimated Net Worth of Michael R Mcdonnell is at least $8.73 Milion dollars as of 16 February 2024. Mr Mcdonnell owns over 6,720 units of Biogen Inc stock worth over $4,082,739 and over the last 20 years he sold BIIB stock worth over $3,080,165. In addition, he makes $1,563,249 as Exec. VP & CFO at Biogen Inc.
Mr has made over 11 trades of the Biogen Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 6,720 units of BIIB stock worth $1,337,885 on 16 February 2024.
The largest trade he's ever made was selling 12,000 units of Biogen Inc stock on 2 January 2020 worth over $1,860,840. On average, Mr trades about 1,647 units every 54 days since 2004. As of 16 February 2024 he still owns at least 20,507 units of Biogen Inc stock.
You can see the complete history of Mr Mcdonnell stock trades at the bottom of the page.
Michael R. McDonnell is the Exec. VP & CFO at Biogen Inc.
As the Exec. VP & CFO of Biogen Inc, the total compensation of Mr McDonnell at Biogen Inc is $1,563,249. There are 7 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900.
Mr McDonnell is 57, he's been the Exec. VP & CFO of Biogen Inc since . There are 14 older and 10 younger executives at Biogen Inc. The oldest executive at Biogen Inc is Stelios Papadopoulos, 72, who is the Independent Chairman of the Board.
Michael's mailing address filed with the SEC is Merit Parkway, Maxfield, South Jordan, Salt Lake County, Utah, 84095, United States.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner oraz Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: